|
1
|
Basu A and Krishnamurthy S: Cellular
responses to cisplatin-induced DNA damage. J Nuleic Acids 2010:
Article ID 201367. 2010.
|
|
2
|
Brozovic A and Osmak M: Activation of
mitogen-activated protein kinases by cisplatin and their role in
cisplatin-resistance. Cancer Lett. 251:1–16. 2007. View Article : Google Scholar
|
|
3
|
Wang Z, Hou J, Lu L, Qi Z, Sun J, Gao W,
Meng J, Wang Y, Sun H, Gu H, et al: Small ribosomal protein subunit
S7 suppresses ovarian tumorigenesis through regulation of the
PI3K/AKT and MAPK pathways. PLoS One. 8:e791172013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bava SV, Puliappadamba VT, Deepti A, Nair
A, Karunagaran D and Anto RJ: Sensitization of taxol-induced
apoptosis by curcumin involves down-regulation of nuclear
factor-kappaB and the serine/threonine kinase Akt and is
independent of tubulin polymerization. J Biol Chem. 280:6301–6308.
2005. View Article : Google Scholar
|
|
5
|
Kang DG, Lee AS, Mun YJ, Woo WH, Kim YC,
Sohn EJ, Moon MK and Lee HS: Butein ameliorates renal concentrating
ability in cisplatin-induced acute renal failure in rats. Biol
Pharm Bull. 27:366–370. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang Y, Chan FL, Chen S and Leung LK: The
plant polyphenol butein inhibits testosterone-induced proliferation
in breast cancer cells expressing aromatase. Life Sci. 77:39–51.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cho SG, Woo SM and Ko SG: Butein
suppresses breast cancer growth by reducing a production of
intracellular reactive oxygen species. J Exp Clin Cancer Res.
33(51)2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yit CC and Das NP: Cytotoxic effect of
butein on human colon adenocarcinoma cell proliferation. Cancer
Lett. 82:65–72. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma CY, Ji WT, Chueh FS, Yang JS, Chen PY,
Yu CC and Chung JG: Butein inhibits the migration and invasion of
SK-HEP-1 human hepatocarcinoma cells through suppressing the ERK,
JNK, p38, and uPA signaling multiple pathways. J Agric Food Chem.
59:9032–9038. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang L, Chen W and Li X: A novel
anticancer effect of butein: Inhibition of invasion through the
ERK1/2 and NF-kappa B signaling pathways in bladder cancer cells.
FEBS Lett. 582:1821–1828. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lau GT, Huang H, Lin SM and Leung LK:
Butein downregulates phorbol 12-myristate 13-acetate-induced COX-2
transcriptional activity in cancerous and non-cancerous breast
cells. Eur J Pharmacol. 648:24–30. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Khan N, Adhami VM, Afaq F and Mukhtar H:
Butein induces apoptosis and inhibits prostate tumor growth in
vitro and in vivo. Antioxid Redox Signal. 16:1195–1204. 2012.
View Article : Google Scholar :
|
|
13
|
Jin ZJ: About the evaluation of drug
combination. Acta Pharmacol Sin. 25:146–147. 2004.PubMed/NCBI
|
|
14
|
Moon DO, Kim MO, Choi YH, Hyun JW, Chang
WY and Kim GY: Butein induces G(2)/M phase arrest and apoptosis in
human hepatoma cancer cells through ROS generation. Cancer Lett.
288:204–213. 2010. View Article : Google Scholar
|
|
15
|
Shiota M, Yokomizo A, Kashiwagi E, Tada Y,
Inokuchi J, Tatsugami K, Kuroiwa K, Uchiumi T, Seki N and Naito S:
Foxo3a expression and acetylation regulate cancer cell growth and
sensitivity to cisplatin. Cancer Sci. 101:1177–1185. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Khatri S, Yepiskoposyan H, Gallo CA,
Tandon P and Plas DR: FOXO3a regulates glycolysis via
transcriptional control of tumor suppressor TSC1. J Biol Chem.
285:15960–15965. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang W, Dolloff NG and El-Deiry WS: ERK
and MDM2 prey on FOXO3a. Nat Cell Biol. 10:125–126. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Germani A, Matrone A, Grossi V, Peserico
A, Sanese P, Liuzzi M, Palermo R, Murzilli S, Campese AF,
Ingravallo G, et al: Targeted therapy against chemoresistant
colorectal cancers: Inhibition of p38α modulates the effect of
cisplatin in vitro and in vivo through the tumor suppressor FoxO3A.
Cancer Lett. 344:110–118. 2014. View Article : Google Scholar
|
|
19
|
Quast SA, Berger A, Plötz M and Eberle J:
Sensitization of melanoma cells for TRAIL-induced apoptosis by
activation of mitochondrialpathways via Bax. Eur J Cell Biol.
93:42–48. 2014. View Article : Google Scholar
|
|
20
|
Kim MJ, Yun HS, Hong EH, Lee SJ, Baek JH,
Lee CW, Yim JH, Kim JS, Park JK, Um HD and Hwang SG: Depletion of
end-binding protein 1 (EB1) promotes apoptosis of human
non-small-cell lung cancer cells via reactive oxygen species and
Bax-mediated mitochondrial dysfunction. Cancer Lett. 339:15–24.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hsu HH, Cheng LH, Ho TJ, Kuo WW, Lin YM,
Chen MC, Lee NH, Tsai FJ, Tsai KH and Huang CY: Apicidin-resistant
HA22T hepato-cellular carcinoma cells massively promote
pro-survival capability via IGF-IR/PI3K/Akt signaling pathway
activation. Tumour Biol. 35:303–313. 2014. View Article : Google Scholar
|
|
22
|
Persons DL, Yazlovitskaya EM, Cui W and
Pelling JC: Cisplatin-induced activation of mitogen-activated
protein kinases in ovarian carcinoma cells: Inhibition of
extracellular signal-regulated kinase activity increases
sensitivity to cisplatin. Clin Cancer Res. 5:1007–1014.
1999.PubMed/NCBI
|
|
23
|
Wang J, Zhou JY and Wu GS: Bim protein
degradation contributes to cisplatin resistance. J Biol Chem.
286:22384–22392. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang X, Martindale JL and Holbrook NJ:
Requirement for ERK activation in cisplatin-induced apoptosis. J
Biol Chem. 275:39435–39443. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang X, Govind S, Sajankila SP, Mi L, Roy
R and Chung FL: Phenethyl isothiocyanate sensitizes human cervical
cancer cells to apoptosis induced by cisplatin. Mol Nutr Food Res.
55:1572–1581. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sheridan C, Brumatti G, Elgendy M, Brunet
M and Martin SJ: An ERK-dependent pathway to Noxa expression
regulates apoptosis by platinum-based chemotherapeutic drugs.
Oncogene. 29:6428–6441. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guégan JP, Ezan F, Théret N, Langouët S
and Baffet G: MAPK signaling in cisplatin-induced death:
Predominant role of ERK1 over ERK2 in human hepatocellular
carcinoma cells. Carcinogenesis. 34:38–47. 2013. View Article : Google Scholar
|
|
28
|
Wang Y, Lin B, Wu J, Zhang H and Wu B:
Metformin inhibits the proliferation of A549/CDDP cells by
activating p38 mitogen-activated protein kinase. Oncol Lett.
8:1269–1274. 2014.PubMed/NCBI
|
|
29
|
Pereira L, Igea A, Canovas B, Dolado I and
Nebreda AR: Inhibition of p38 MAPK sensitizes tumour cells to
cisplatin-induced apoptosis mediated by reactive oxygen species and
JNK. EMBO Mol Med. 5:1759–1774. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Feng R, Zhai WL, Yang HY, Jin H and Zhang
QX: Induction of ER stress protects gastric cancer cells against
apoptosis induced by cisplatin and doxorubicin through activation
of p38 MAPK. Biochem Biophys Res Commun. 406:299–304. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Esteva FJ, Sahin AA, Smith TL, Yang Y,
Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN and Bacus
SS: Prognostic significance of phosphorylated P38 mitogen-activated
protein kinase and HER-2 expression in lymph node-positive breast
carcinoma. Cancer. 100:499–506. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang SN, Lee KT, Tsai CJ, Chen YJ and Yeh
YT: Phosphorylated p38 and JNK MAPK proteins in hepatocellular
carcinoma. Eur J Clin Invest. 42:1295–1301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dolado I, Swat A, Ajenjo N, De Vita G,
Cuadrado A and Nebreda AR: p38alpha MAP kinase as a sensor of
reactive oxygen species in tumorigenesis. Cancer Cell. 11:191–205.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Voisset E, Oeztuerk-Winder F, Ruiz EJ and
Ventura JJ: p38α negatively regulates survival and malignant
selection of transformed bronchioalveolar stem cells. PLoS One.
8:e789112013. View Article : Google Scholar
|
|
35
|
Piaggi S, Raggi C, Corti A, Pitzalis E,
Mascherpa MC, Saviozzi M, Pompella A and Casini AF: Glutathione
transferase omega 1–1 (GSTO1–1) plays an anti-apoptotic role in
cell resistance to cisplatin toxicity. Carcinogenesis. 31:804–811.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ishitsuka A, Fujine E, Mizutani Y, Tawada
C, Kanoh H, Banno Y and Seishima M: FTY720 and cisplatin
synergistically induce the death of cisplatin-resistant melanoma
cells through the down-regulation of the PI3K pathway and the
decrease in epidermal growth factor receptor expression. Int J Mol
Med. 34:1169–1174. 2014.PubMed/NCBI
|
|
37
|
Berra E, Diaz-Meco MT and Moscat J: The
activation of p38 and apoptosis by the inhibition of Erk is
antagonized by the phosphoinositide 3-kinase/Akt pathway. J Biol
Chem. 273:10792–10797. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chiacchiera F, Grossi V, Cappellari M,
Peserico A, Simonatto M, Germani A, Russo S, Moyer MP, Resta N,
Murzilli S, et al: Blocking p38/ERK crosstalk affects colorectal
cancer growth by inducing apoptosis in vitro and in preclinical
mouse models. Cancer Lett. 324:98–108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang
F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, et al: IkappaB kinase
promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell.
117:225–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang JY, Zong CS, Xia W, Yamaguchi H, Ding
Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, et al: ERK promotes
tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation.
Nat Cell Biol. 10:138–148. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chiacchiera F, Matrone A, Ferrari E,
Ingravallo G, Lo Sasso G, Murzilli S, Petruzzelli M, Salvatore L,
Moschetta A and Simone C: p38alpha blockade inhibits colorectal
cancer growth in vivo by inducing a switch from HIF1alpha- to
FoxO-dependent transcription. Cell Death Differ. 16:1203–1214.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chiacchiera F and Simone C: Inhibition of
p38alpha unveils an AMPK-FoxO3A axis linking autophagy to
cancer-specific metabolism. Autophagy. 5:1030–1033. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang X, Tang N, Hadden TJ and Rishi AK:
Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta.
1813:1978–1986. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ho KK, Myatt SS and Lam EW: Many forks in
the path: Cycling with FoxO. Oncogene. 27:2300–2311. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Schmidt M, Fernandez de Mattos S, van der
Horst A, Klompmaker R, Kops GJ, Lam EW, Burgering BM and Medema RH:
Cell cycle inhibition by FoxO forkhead transcription factors
involves downregulation of cyclin D. Mol Cell Biol. 22:7842–7852.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Massagué J: G1 cell-cycle control and
cancer. Nature. 432:298–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lee MT, Ho SM, Tarapore P, Chung I and
Leung YK: Estrogen receptor β isoform 5 confers sensitivity of
breast cancer cell lines to chemotherapeutic agent-induced
apoptosis through interaction with Bcl2L12. Neoplasia.
15:1262–1271. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kiyoshima T1, Yoshida H, Wada H, Nagata K,
Fujiwara H, Kihara M, Hasegawa K, Someya H and Sakai H:
Chemoresistance to concanamycin A1 in human oral squamous cell
carcinoma is attenuated by an HDAC inhibitor partly via suppression
of Bcl-2 expression. PLoS One. 8:e809982013. View Article : Google Scholar : PubMed/NCBI
|
